Registration for a live webinar on 'Neuroleptic malignant syndrome' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Disclosure
- Chronic urticaria
- Chronic urticaria classification
- Chronic spontaneous urticaria
- Prevalence of chronic urticaria
- Chronic urticaria in adults
- Chronic urticaria in children
- Patients have low quality of life
- Angioedema in CSU
- Occurrences of angioedema in CSU
- Severity of angioedema in CSU
- How CU affects sleep
- What CU does to patients
- Comorbidities of CSU
- Comorbidities lower QoL further
- CSU is chronic
- CU is chronic
- CU does not improve by itself
- CU is often poorly controlled
- Doctors’ views of CSU patients
- Chronic urticaria is…
- Classification of urticarias
- Identifying the type of CU
- CSU diagnostic workup
- Differential diagnoses
- Rule out severe inflammatory disease
- Measure CSU activity and impact
- Urticaria Activity Score (UAS7)
- Urticaria Control Test (UCT)
- CSU is driven by mast cells
- Mast cell degranulation
- Mast cell degranulation in CSU
- The role of FcεRI in CSU
- Patients often have IgE-anti-TPO
- The benefit of omalizumab
- The cause of mast cell degranulation (1)
- The cause of mast cell degranulation (2)
- CSU patients have more auto-IgE
- IgE against autoantigens in CSU
- IL-24 as an autoantigen in CSU
- Auto-IgE leads to elevated total IgE
- Type I autoimmune CSU
- Type IIb autoimmune CSU (1)
- Type IIb autoimmune CSU (2)
- CSU is an autoimmune disease
Topics Covered
- Chronic urticaria classification
- Chronic urticaria prevalence and low quality of life
- Angioedema in CSU (Chronic Spontaneous Urticaria)
- Comorbidities of CSU
- CSU diagnostic workup
- Measure CSU activity impact & control
- CSU is an autoimmune disease
- Type I & Type IIb autoimmune CSU
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Maurer, M. (2024, July 17). Chronic spontaneous and inducible urticaria 1 [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved October 8, 2024, from https://doi.org/10.69645/YXHW3652.Export Citation (RIS)
Publication History
Financial Disclosures
- Professor Maurer has received research funding from Deutsche Forschungsgemeinschaft (DFG), EU (FP7, COST), European Centre of Allergy Research Foundation (ECARF), Urticaria Network e.V. (UNEV), Bayer, Leo, Novartis, Riemser, and Uriach. He is a speaker and/org advisor for Allakos, Almirall Hermal, Bayer, BioCryst, Dyax, FAES, Genentech, Leo, Merckle Recordati, Moxie, MSD, Novartis, Pharvaris, Riemser, Sanofi Aventis, Shire, Takeda, Tribute Pharmaceuticals, UCB, and Uriach.
Chronic spontaneous and inducible urticaria 1
Other Talks in the Series: Allergy - From Basics to Clinic
Transcript
Please wait while the transcript is being prepared...
0:00
Hello and a very warm welcome from Charité here in Berlin.
My name is Marcus Maurer and I'm very happy that you have the time to join us
in our review of "Chronic Spontaneous and Chronic Inducible Urticaria".
What we'll be doing over the next 60 minutes is to discuss new data on chronic urticaria.
All of this of clinical relevance,
we will start with looking at the burden of disease,
the epidemiology, and also the state of how patients are treated in clinical practice.
We will then talk about the diagnostic workup and end up with
therapeutic approaches for patients with
chronic spontaneous and chronic inducible urticaria.
0:46
Chronic urticaria is a disease characterized by
itchy wheals and angioedema or angioedema.
It is important to understand that these two signs and symptoms,
wheals and angioedema can be present in patients both of
them or just wheals or just angioedema.
1:08
In our current classification of chronic urticaria,
we distinguish between spontaneous urticaria and inducible urticaria.
There is a group of inducible urticarias which are then subgrouped again,
you can see this on the right side of the slide,
into physical urticarias and other inducible urticarias.
What is common to all inducible urticaria is that there is a specific,
a definite trigger that needs to be there in order for wheals,
angioedema, or both to happen.
When this trigger, for example,
cold in cold urticaria is not present there are no wheals,
there is no angioedema.
But every time this trigger is present,
patients will suffer the consequences.
In contrast, spontaneous urticaria is characterized
by wheals and angioedema that come seemingly out of the blue,
and there is no definite trigger that can be linked to the signs and symptoms.